Opus Genetics IRD Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Operating margin | -359.1%+112pp | -271.9%+293pp | -445.4%-93.7pp | -420.7%-329pp | -471%-407pp | |
| Net margin | -892.4%-463pp | -349.3%+174pp | -466.1%-142pp | -377.9%-292pp | -429.4%-370pp | |
| EBITDA margin | -358.7%+112pp | -271.5%+293pp | -445.1%-93.4pp | -420.4%-329pp | -470.8%-407pp | |
| Returns | ||||||
| Return on assets | -186%-68.8pp | -113.9%+12.8pp | -178.3%-121pp | -139.6%-108pp | -117.2%-94.0pp | |
| Efficiency | ||||||
| Asset turnover | 0.2×-0.1× | 0.3×+0.1× | 0.4×+0.2× | 0.4×0.0× | 0.3×-0.1× | |
| Liquidity | ||||||
| Current ratio | 7.1×+5.2× | 6.4×+3.2× | 1.2×-5.4× | 1.9×-8.8× | 2×-7.0× | |
| Quick ratio | 7.1×+5.2× | 6.4×+3.2× | 1.2×-5.4× | 1.9×-8.8× | 2×-7.0× | |
| Cash ratio | 6.4×+4.7× | 5.8×+3.1× | 1.1×-5.0× | 1.6×-8.3× | 1.7×-6.4× | |
| Leverage | ||||||
| Debt-to-assets | 0×— | 0×— | 0×— | 0×— | —— | |
| Interest coverage | -217.3×— | -299.2×— | -958.5×— | —— | —— | |
| Per Share | ||||||
| Book value per share | -$0.53-452% | $0.25-2.0% | $0.08-93.6% | $0.28-82.5% | $0.15-92.0% | |
| Valuation | ||||||
| Market capitalization | $307.14M+442% | $138.62M+269% | $98.85M— | $55.1M— | $44.15M— | |
| Enterprise value | $248.38M— | $94.66M— | $69.1M— | $23.67M— | —— | |
| Price / sales | 25.6×+21.5× | 9.8×+6.3× | 6.8×— | 3.6×— | 3.2×— | |
| EV / sales | 20.7×— | 6.7×— | 4.7×— | 1.5×— | —— | |
| Earnings yield | -34.8%+68.6pp | -35.8%+117pp | -69%— | -105.8%— | -132.8%— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Opus Genetics's ratios come from?
- Every ratio is computed from Opus Genetics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
